Martin Dieck

Martin Dieck has held a variety of roles in the medical industry since 2016. In that year, they were the Managing Member of Neuro Technology Investors, LLC and the Chairman of Serenity Medical, Inc and Comet Medical. In 2017, they became the Executive Chairman of Cerebrotech Medical Systems. In 2018, they were appointed Board Member of Maduro Medical (formerly Maduro Manufacturing), Basecamp Vascular, and Spinnaker Medical. In 2019, they became a Director of Turtle Conservancy. In 2020, they were appointed Board Member of Neuro Radial Technologies NRT. Most recently, in 2021, they were appointed Chairman of Synchron, where they are developing the STENTRODE™ - the world's first endovascular brain machine interface.

Martin Dieck attended Fremont High School before earning a BA in Biology from Willamette University between 1985 and 1989. Martin then went on to pursue an MBA from the University of California, Berkeley, Haas School of Business, which they completed in 1993.